Fly Intel: What to watch in Intuitive Surgical earnings report » 13:3101/2301/23/20
ISRG, MDT, TRXC, JNJ
Intuitive Surgical (ISRG)…
Intuitive Surgical (ISRG) is scheduled to report the results of its fourth fiscal quarter after the market close on Thursday, January 23, with a conference call scheduled for 4:30 pm EDT. What to watch: 1. PROCEDURAL GROWTH: Along with its third quarter report in October, Intuitive Surgical expanded its FY19 procedure growth view to 17%-18% from 16%-17%. U.S. general surgery procedures and worldwide urologic procedures were the catalysts to an increase of Worldwide da Vinci procedures growth of approximately 20% in Q3. "Intuitive's performance in our second quarter was solid. Our teams remain focused on helping our customers improve outcomes and lower the total cost to treat per patient episode for their patient populations," said Intuitive CEO Gary Guthart. 2. PRELIMINARY RESULTS: On January 9, Intuitive reported preliminary Q4 results ahead of its participation at the 38th Annual JP Morgan Healthcare Conference. According to the company, worldwide da Vinci procedures increased by approximately 19% in Q4 compared with Q4 of 2018. FY19 worldwide da Vinci procedures increased by approximately 18% compared with FY18. Preliminary Q4 revenue of $1.278B grew 22% compared with $1.047B for Q418. Preliminary 2019 revenue of $4.479B grew 20% compared with $3.724B for 2018. Analysts had been projecting that that Intuitive would report revenue of $1.22B. 3. CORPORATE DEVELOPMENTS: In 2019, The FDA approved Intuitive's Ion endoluminal system to enable minimally invasive biopsy in the peripheral lung. Additionally, this past December, reports indicated that Congress would move to permanently repeal three major health industry taxes that were originally implemented to help pay for "Obamacare." Congressional lawmakers have agreed to repeal the "Cadillac tax" on expensive employer plans, repeal a tax on medical devices and repeal a health insurance fee. In Late November, Intuitive announced FDA clearance of two innovative technologies for two of the company's da Vinci surgical systems to help improve procedures that require sealing. 4. COMPETITION: Intuitive is facing competitive threats from Medtronic (MDT), Transenterix (TRXC), and Johnson & Johnson (JNJ), which acquired Auris Health in 2019, and whose Monarch platform is used for diagnostic and therapeutic bronchoscopic procedures.
Janssen announces EC approval for expanded use of Stelara in young children » 11:2701/2301/23/20
Earlier, the Janssen…
Earlier, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission has approved the expanded use of Stelara for the treatment of pediatric patients ages 6-11 with moderate to severe plaque psoriasis. "Ustekinumab was previously approved for use in adolescent and adult patients with plaque psoriasis, aged 12 years and older, and is now the first available biologic treatment in this patient population to selectively address the IL-23/IL-12 pathway, an important therapeutic target for the condition," the company stated.
Fly Intel: Wall Street's top stories for Wednesday » 16:4701/2201/22/20
IBM, NFLX, JNJ, AAPL, DIS, ETN, BA, TSLA, ABT, NAVI, ARNC, FCEL, NTRS
Stocks were rebounding…
Unusually active option classes on open January 22nd » 09:4001/2201/22/20
CRK, VOD, AAL, SHAK, USO, JNJ, CTL, EBAY, UBER, BYND
Unusual total active…
Unusual total active option classes on open include: Comstock Resources (CRK), Vodafone (VOD), American Airlines (AAL), Shake Shack (SHAK), United States Oil Fund (USO), Johnson & Johnson (JNJ), CenturyLink (CTL), EBay (EBAY), Uber (UBER), and Beyond Meat (BYND).
Johnson & Johnson says 'cautiously optimistic' on opioid settlement talks 09:0201/2201/22/20
Johnson & Johnson sees FY20 adj. pre-tax operating margin up ~100 bps » 08:4801/2201/22/20
Sees FY20 effective tax…
Sees FY20 effective tax rate 17.5%-18.5%.
Johnson & Johnson says sees no major acquisitions in 2020 08:4501/2201/22/20
Johnson & Johnson says sees FY20 free cash flow down due to opioid charge 08:4301/2201/22/20
Johnson & Johnson says well-positioned to deliver above-market growth in 2020 » 08:3601/2201/22/20
Says exceeded performance…
Says exceeded performance goals in 2019. Says focused on the long-term, driving innovation. Comments taken from Q4 earnings conference call.
Johnson & Johnson down 1.5% after reporting Q4 results 07:1301/2201/22/20